Reed Jobs is an individual who is enjoyable to be around. He’s extremely talkative, constantly criticizing himself, inclined to use video-game comparisons, and it’s evident that he is passionate about his job. Although he isn’t particularly keen on discussing his status as Steve Jobs’s son, he isn’t overly concerned or tense about it. When Maggie inquired if he was using a MacBook for our video call on Thursday, he promptly responded, “Are you serious? “What he would prefer to discuss is Yosemite, the venture firm he founded in 2023, which focuses on oncology and aims to construct biotech companies from initial academic research. This is done by combining philanthropy and external investment capital. After three years, Jobs has high aspirations for Yosemite to become a significant force, not only because he aims to win but also because he believes the potential before him is growing more rapidly than anticipated due to AI’s influence on drug discovery and clinical trial design. Among the portfolio companies that he takes the most pride in are Azalea, which originated from a grant to Jennifer Doudna’s lab and is now in clinical trials, and Quarry, a company created with serial founder Craig Crews based on a unique therapeutic method called induced proximity. This approach involves a drug physically pulling a disease-causing protein next to the cell’s own breakdown system, rather than trying to block it directly. When we last spoke with Jobs at TechCrunch Disrupt nearly three years ago, Yosemite was newly established, and the biotech industry was recovering from its post-pandemic downturn. Currently, the company has a workforce of 17 members, and a group of successful medicines are experiencing the expiration of their patent rights within the same timeframe, leading to various new prospects. Additionally, AI has evolved from being a novel concept to a significant component of Yosemite’s operations, as described by Jobs. We discussed everything.. The Q&A has been shortened.. TC: You revealed the initial closing of your second fund earlier this year, aiming for $350 million.
